Stock fact sheet · data as of
Lakewood-Amedex Biotherapeutics, Inc. (LABT): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is LABT undervalued?
At 0.6124 (close of 16 Oct 2026), LABT has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -5.18, it pays no dividend and its debts exceed what its assets would fetch), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.
The nightly engine files LABT under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for LABT
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -1.22 | -300% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Lakewood-Amedex Biotherapeutics, Inc. scores only 0 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 0.0/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are high - ROIC 1264.9%, ROE 195.9%, ROA -798.9% - with debt at -0.85 times equity and negative free cash flow.
Lakewood-Amedex Biotherapeutics, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 0 / 9 | ROIC | 1264.9% |
|---|---|---|---|
| GLS Moat | 0.0 / 10 | ROE | 195.9% |
| Debt / equity | -0.85 | ROA | -798.9% |
| Free-cash-flow yield | -325.1% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 20: No options
No options are listed on Lakewood-Amedex Biotherapeutics, Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 20) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 148k shares a day on a market cap of $1M, with a beta of -4.76 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 7 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 13 / 25 | 0% margin of safety | |
| Health | 0 / 20 | Piotroski 0/9 | |
| Moat | 0 / 15 | moat 0.0/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 7 / 20 | 148k shares/day, $1M cap, beta -4.76 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for LABT in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Lakewood-Amedex Biotherapeutics, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| BBLG Bone Biologics Corporation | 0.3876 | 4.22 | +91% | 36No options | $1M |
| MTNB Matinas BioPharma Holdings, Inc. | 2.42 | 6.45 | +62% | 33No options | $1M |
| GNPX Genprex, Inc. | 2.29 | 168.15 | +99% | 39No options | $1M |
| CRIS Curis, Inc. | 0.5080 | - | - | 20No options | $991K |
| NCEL NewcelX Ltd. | 2.85 | 4.47 | +36% | 35No options | $1M |
| SILO Silo Pharma, Inc. | 1.20 | 6.63 | +82% | 35No options | $1M |
| MLEC Moolec Science S.A. | 1.87 | 8,260.03 | +100% | 39No options | $1M |
| PPCB Propanc Biopharma, Inc. | 0.3657 | 0.2233 | -64% | 13No options | $833K |
| ATXI Avenue Therapeutics, Inc. | 0.4300 | 15.31 | +97% | 36No options | $1M |
| RADX Radiopharm Theranostics Limited | 1.12 | - | - | 21No options | $1M |
| PTIX Protagenic Therapeutics, Inc. | 0.8000 | 26.61 | +97% | 39No options | $1M |
| HXBM Helix BioMedix, Inc. | 3.29 | - | - | 22No options | $739K |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about LABT
Is LABT undervalued right now?
The GLS models could not value LABT (the company lost money over the last twelve months, EPS -5.18, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 0.6124 against.
What is the Wheel Score of LABT and what does it mean?
LABT has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for LABT?
None of the nine GLS models produced a positive value for LABT (the company lost money over the last twelve months, EPS -5.18, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.
When does Lakewood-Amedex Biotherapeutics, Inc. report earnings next?
No upcoming earnings date is recorded for LABT in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does LABT have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on LABT, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.